{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:56:41Z","timestamp":1781639801432,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2019-107561RB-I00"],"award-info":[{"award-number":["PID2019-107561RB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PID2022-136391OB-100"],"award-info":[{"award-number":["PID2022-136391OB-100"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Downregulation of major histocompatibility complex class I (MHC-I) molecules is a frequent mechanism of tumor immune evasion, impairing recognition and elimination of cancer cells by cytotoxic CD8+ T lymphocytes. This phenotype, associated with poor prognosis and resistance to immune checkpoint blockade, is often driven by oncogenic pathways that reversibly suppress MHC-I. The MAPK ERK5 and its only upstream activating kinase MEK5 configure a unique intracellular signaling that regulates cell proliferation, differentiation and survival, and it has emerged as an oncogenic driver of different tumors. In this work, we investigated whether the ERK5 pathway contributes to cellular immunity. We used a panel of human cancer cell lines representing three well-established oncogenic contexts linked to reversible MHC-I downregulation (MYCN amplification, PTEN\/PIK3CA mutations, and androgen receptor signaling), together with control cellular models exhibiting constitutively high MHC-I expression. We found that MEK5 or ERK5 pharmacologic inhibition or ERK5 targeted degradation increased MHC-I surface and total expression in low-MHC-I cells, without affecting PD-L1 levels. Conversely, ERK5 overexpression impaired MHC-I levels. Moreover, systemic administration of an ERK5 inhibitor also enhanced MHC-I expression in tumor xenografts. Mechanistically, RT-qPCR analysis showed that ERK5 or MEK5 inhibition did not significantly modify transcription of classical HLA-I genes or antigen-processing machinery components, and RNA-seq analysis did not render enrichment of MHC-I transcriptional programs in response to ERK5 inhibition. In contrast, trafficking experiments implicated the ERK5 pathway in the regulation of MHC-I lysosomal degradation, suggesting that ERK5 controls surface MHC-I through post-translational mechanisms. Notably, functional assays were carried out in co-cultures of cancer cells with tumor-specific human CD8+ T cells, where ERK5 inhibition sensitized MYCN-amplified or PTEN\/PI3KCA-mutated cancer cells to CD8\u2009+\u2009T cell-mediated apoptosis. These results identify ERK5 as a novel regulator of MHC-I expression in cancer cells, by regulating antigen presentation across diverse oncogenic contexts, and support a rationale for the use of ERK5 inhibitors as a strategy to improve the efficacy of immune checkpoint blockade-based immunotherapy.<\/jats:p>","DOI":"10.1186\/s12964-026-02780-9","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T01:53:23Z","timestamp":1773021203000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MAPK ERK5 is a novel regulator of MHC-I in cancer cells"],"prefix":"10.1186","volume":"24","author":[{"given":"Maria","family":"Vi\u00f1as-Casas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Lizcano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"2780_CR1","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30:R921\u20135.","journal-title":"Curr Biol"},{"key":"2780_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346.","journal-title":"Cancer Discov"},{"key":"2780_CR3","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00262-010-0893-2","volume":"59","author":"F Garrido","year":"2010","unstructured":"Garrido F, Algarra I, Garcia-Lora AM. The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible \u201chard\u201d lesions. Cancer Immunol Immunother. 2010;59:1601\u20136.","journal-title":"Cancer Immunol Immunother"},{"key":"2780_CR4","doi-asserted-by":"publisher","first-page":"636568","DOI":"10.3389\/fimmu.2021.636568","volume":"12","author":"K Dhatchinamoorthy","year":"2021","unstructured":"Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer immune evasion through loss of MHC class I antigen presentation. Front Immunol. 2021;12:636568.","journal-title":"Front Immunol"},{"key":"2780_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","volume":"24","author":"BH Alsaafeen","year":"2025","unstructured":"Alsaafeen BH, Ali BR, Elkord E. Resistance mechanisms to immune checkpoint inhibitors: updated insights. Mol Cancer. 2025;24:20.","journal-title":"Mol Cancer"},{"key":"2780_CR6","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-023-01899-4","volume":"22","author":"X Wu","year":"2023","unstructured":"Wu X, Li T, Jiang R, Yang X, Guo H, Yang R. Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects. Mol Cancer. 2023;22:194.","journal-title":"Mol Cancer"},{"key":"2780_CR7","first-page":"37","volume":"1825","author":"BA Drew","year":"2012","unstructured":"Drew BA, Burow ME, Beckman BS. MEK5\/ERK5 pathway: the first fifteen years. Biochim Biophys Acta. 2012;1825:37\u201348.","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"2780_CR8","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.3390\/ijms20061426","volume":"20","author":"B Stecca","year":"2019","unstructured":"Stecca B, Rovida E. Impact of ERK5 on the hallmarks of cancer. Int J Mol Sci. 2019;20(6):1426. https:\/\/doi.org\/10.3390\/ijms20061426.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2780_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3390\/biom11020183","volume":"11","author":"AB Bhatt","year":"2021","unstructured":"Bhatt AB, Patel S, Matossian MD, Ucar DA, Miele L, Burow ME, et al. Molecular mechanisms of epithelial to mesenchymal transition regulated by ERK5 signaling. Biomolecules. 2021;11(2):183.","journal-title":"Biomolecules"},{"key":"2780_CR10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41698-021-00218-8","volume":"5","author":"A Sanchez-Fdez","year":"2021","unstructured":"Sanchez-Fdez A, Re-Louhau MF, Rodriguez-Nunez P, Ludena D, Matilla-Almazan S, Pandiella A, et al. Clinical, genetic and pharmacological data support targeting the MEK5\/ERK5 module in lung cancer. NPJ Precis Oncol. 2021;5:78.","journal-title":"NPJ Precis Oncol"},{"key":"2780_CR11","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/s12276-023-01008-x","volume":"55","author":"A Sanchez-Fdez","year":"2023","unstructured":"Sanchez-Fdez A, Matilla-Almazan S, Del Carmen S, Abad M, Arconada-Luque E, Jimenez-Suarez J, et al. Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications. Exp Mol Med. 2023;55:1247\u201357.","journal-title":"Exp Mol Med"},{"key":"2780_CR12","doi-asserted-by":"publisher","first-page":"e69291","DOI":"10.1371\/journal.pone.0069291","volume":"8","author":"JW Antoon","year":"2013","unstructured":"Antoon JW, Martin EC, Lai R, Salvo VA, Tang Y, Nitzchke AM, et al. MEK5\/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis. PLoS ONE. 2013;8:e69291.","journal-title":"PLoS ONE"},{"key":"2780_CR13","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1158\/0008-5472.CAN-13-3043","volume":"75","author":"KG Finegan","year":"2015","unstructured":"Finegan KG, Perez-Madrigal D, Hitchin JR, Davies CC, Jordan AM, Tournier C. Erk5 is a critical mediator of inflammation-driven cancer. Cancer Res. 2015;75:742\u201353.","journal-title":"Cancer Res"},{"key":"2780_CR14","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/sj.bjc.6606062","volume":"104","author":"AK Ramsay","year":"2011","unstructured":"Ramsay AK, McCracken SR, Soofi M, Fleming J, Yu AX, Ahmad I, et al. Erk5 signalling in prostate cancer promotes an invasive phenotype. Br J Cancer. 2011;104:664\u201372.","journal-title":"Br J Cancer"},{"key":"2780_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.18632\/oncoscience.135","volume":"2","author":"M Miranda","year":"2015","unstructured":"Miranda M, Rozali E, Khanna KK, Al-Ejeh F. MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments. Oncoscience. 2015;2:99\u2013101.","journal-title":"Oncoscience"},{"key":"2780_CR16","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s00018-022-04541-6","volume":"79","author":"N Dieguez-Martinez","year":"2022","unstructured":"Dieguez-Martinez N, Espinosa-Gil S, Yoldi G, Megias-Roda E, Bolinaga-Ayala I, Vinas-Casas M, et al. The ERK5\/NF-kappaB signaling pathway targets endometrial cancer proliferation and survival. Cell Mol Life Sci. 2022;79:524.","journal-title":"Cell Mol Life Sci"},{"key":"2780_CR17","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.humpath.2011.08.003","volume":"43","author":"F Tesser-Gamba","year":"2012","unstructured":"Tesser-Gamba F, Petrilli AS, de Seixas Alves MT, Filho RJ, Juliano Y, Toledo SR. MAPK7 and MAP2K4 as prognostic markers in osteosarcoma. Hum Pathol. 2012;43:994\u20131002.","journal-title":"Hum Pathol"},{"key":"2780_CR18","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1136\/gutjnl-2014-306761","volume":"64","author":"E Rovida","year":"2015","unstructured":"Rovida E, Di MG, Tusa I, Cannito S, Paternostro C, Navari N, et al. The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma. Gut. 2015;64:1454\u201365.","journal-title":"Gut"},{"key":"2780_CR19","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.molmed.2020.01.006","volume":"26","author":"DM Pereira","year":"2020","unstructured":"Pereira DM, Rodrigues CMP. Targeted avenues for cancer treatment: the MEK5-ERK5 signaling pathway. Trends Mol Med. 2020;26:394\u2013407.","journal-title":"Trends Mol Med"},{"key":"2780_CR20","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1158\/2326-6066.CIR-16-0177","volume":"4","author":"EJ Brea","year":"2016","unstructured":"Brea EJ, Oh CY, Manchado E, Budhu S, Gejman RS, Mo G, et al. Kinase regulation of human MHC class I molecule expression on cancer cells. Cancer Immunol Res. 2016;4:936\u201347.","journal-title":"Cancer Immunol Res"},{"key":"2780_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/cac2.12117","volume":"41","author":"Z Liu","year":"2021","unstructured":"Liu Z, Ning F, Cai Y, Sheng H, Zheng R, Yin X, et al. The EGFR-P38 MAPK axis up-regulates PD-L1 through miR-675-5p and down-regulates HLA-ABC via hexokinase-2 in hepatocellular carcinoma cells. Cancer Commun (Lond). 2021;41:62\u201378.","journal-title":"Cancer Commun (Lond)"},{"key":"2780_CR22","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.chembiol.2022.09.004","volume":"29","author":"I You","year":"2022","unstructured":"You I, Donovan KA, Krupnick NM, Boghossian AS, Rees MG, Ronan MM, et al. Acute pharmacological degradation of ERK5 does not inhibit cellular immune response or proliferation. Cell Chem Biol. 2022;29:1630-1638 e1637.","journal-title":"Cell Chem Biol"},{"key":"2780_CR23","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41419-023-06229-6","volume":"14","author":"S Espinosa-Gil","year":"2023","unstructured":"Espinosa-Gil S, Ivanova S, Alari-Pahissa E, Denizli M, Villafranca-Magdalena B, Vinas-Casas M, et al. Map kinase ERK5 modulates cancer cell sensitivity to extrinsic apoptosis induced by death-receptor agonists. Cell Death Dis. 2023;14:715.","journal-title":"Cell Death Dis"},{"key":"2780_CR24","doi-asserted-by":"publisher","first-page":"742049","DOI":"10.3389\/fcell.2021.742049","volume":"9","author":"A Gamez-Garcia","year":"2021","unstructured":"Gamez-Garcia A, Bolinaga-Ayala I, Yoldi G, Espinosa-Gil S, Dieguez-Martinez N, Megias-Roda E, et al. Erk5 inhibition induces autophagy-mediated cancer cell death by activating ER stress. Front Cell Dev Biol. 2021;9:742049.","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"2780_CR25","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.3390\/ijms21062203","volume":"21","author":"T Erazo","year":"2020","unstructured":"Erazo T, Espinosa-Gil S, Dieguez-Martinez N, Gomez N, Lizcano JM. SUMOylation is required for ERK5 nuclear translocation and ERK5-mediated cancer cell proliferation. Int J Mol Sci. 2020;21(6):2203.","journal-title":"Int J Mol Sci"},{"key":"2780_CR26","doi-asserted-by":"publisher","first-page":"112944","DOI":"10.1016\/j.celrep.2023.112944","volume":"42","author":"X Ma","year":"2023","unstructured":"Ma X, Wang Q, Sun C, Agarwal I, Wu H, Chen J, et al. Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8(+) T cell exhaustion via TRIM14-IFN-beta axis. Cell Rep. 2023;42:112944.","journal-title":"Cell Rep"},{"issue":"9","key":"2780_CR27","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1021\/acschembio.7b00638","volume":"13","author":"J Wang","year":"2018","unstructured":"Wang J, Erazo T, Ferguson FM, Buckley DL, Gomez N, Mu\u00f1oz-Guardiola P, et al. Structural and atropisomeric factors governing the selectivity of pyrimido-benzodiazipinones as inhibitors of kinases and bromodomains. ACS Chem Biol. 2018;13(9):2438\u201348.","journal-title":"ACS Chem Biol."},{"key":"2780_CR28","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.ccell.2018.10.001","volume":"34","author":"AV Vaseva","year":"2018","unstructured":"Vaseva AV, Blake DR, Gilbert TSK, Ng S, Hostetter G, Azam SH, et al. KRAS suppression-induced degradation of MYC is antagonized by a MEK5-ERK5 compensatory mechanism. Cancer Cell. 2018;34:807-822 e807.","journal-title":"Cancer Cell"},{"issue":"6","key":"2780_CR29","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1080\/15548627.2020.1761651","volume":"17","author":"P Munoz-Guardiola","year":"2020","unstructured":"Munoz-Guardiola P, Casas J, Megias-Roda E, Sole S, Perez-Montoyo H, Yeste-Velasco M, et al. The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells. Autophagy. 2020;17(6):1349\u201366.","journal-title":"Autophagy"},{"issue":"19","key":"2780_CR30","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.3390\/cancers16193272","volume":"16","author":"E Xanthopoulou","year":"2024","unstructured":"Xanthopoulou E, Lamprou I, Mitrakas AG, Michos GD, Zois CE, Giatromanolaki A, et al. Autophagy blockage up-regulates HLA-class-I molecule expression in lung cancer and enhances anti-PD-L1 immunotherapy efficacy. Cancers (Basel). 2024;16(19):3272. https:\/\/doi.org\/10.3390\/cancers16193272.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2780_CR31","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.3390\/cancers12071760","volume":"12","author":"AM Cornel","year":"2020","unstructured":"Cornel AM, Mimpen IL, Nierkens S. MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy. Cancers (Basel). 2020;12(7):1760. https:\/\/doi.org\/10.3390\/cancers12071760.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2780_CR32","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3390\/cancers14020348","volume":"14","author":"M Monti","year":"2022","unstructured":"Monti M, Celli J, Missale F, Cersosimo F, Russo M, Belloni E, et al. Clinical significance and regulation of ERK5 expression and function in cancer. Cancers (Basel). 2022;14(2):348. https:\/\/doi.org\/10.3390\/cancers14020348.","journal-title":"Cancers (Basel)"},{"key":"2780_CR33","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1042\/BCJ20210646","volume":"478","author":"HA Brown","year":"2021","unstructured":"Brown HA, Williams CAC, Zhou H, Rios-Szwed D, Fernandez-Alonso R, Mansoor S, et al. An ERK5-KLF2 signalling module regulates early embryonic gene expression and telomere rejuvenation in stem cells. Biochem J. 2021;478:4119\u201336.","journal-title":"Biochem J"},{"key":"2780_CR34","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/j.yexcr.2008.10.026","volume":"315","author":"JA Nathan","year":"2009","unstructured":"Nathan JA, Lehner PJ. The trafficking and regulation of membrane receptors by the RING-CH ubiquitin E3 ligases. Exp Cell Res. 2009;315:1593\u2013600.","journal-title":"Exp Cell Res"},{"key":"2780_CR35","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/0092-8674(86)90509-X","volume":"47","author":"R Bernards","year":"1986","unstructured":"Bernards R, Dessain SK, Weinberg RA. N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastoma. Cell. 1986;47:667\u201374.","journal-title":"Cell"},{"key":"2780_CR36","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nm1517","volume":"13","author":"AT Parsa","year":"2007","unstructured":"Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13:84\u20138.","journal-title":"Nat Med"},{"key":"2780_CR37","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1158\/2159-8290.CD-24-0559","volume":"15","author":"LN Chesner","year":"2025","unstructured":"Chesner LN, Polesso F, Graff JN, Hawley JE, Smith AK, Lundberg A, et al. Androgen receptor inhibition increases MHC class I expression and improves immune response in prostate cancer. Cancer Discov. 2025;15:481\u201394.","journal-title":"Cancer Discov"},{"key":"2780_CR38","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.4049\/jimmunol.1001250","volume":"185","author":"S Charni","year":"2010","unstructured":"Charni S, de BG, Rathore MG, Aguilo JI, van den Elsen PJ, Haouzi D, et al. Oxidative phosphorylation induces de novo expression of the MHC class I in tumor cells through the ERK5 pathway. J Immunol. 2010;185:3498\u2013503.","journal-title":"J Immunol"},{"key":"2780_CR39","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1021\/acs.jmedchem.3c00072","volume":"66","author":"DC Miller","year":"2023","unstructured":"Miller DC, Harnor SJ, Martin MP, Noble RA, Wedge SR, Cano C. Modulation of ERK5 activity as a therapeutic anti-cancer strategy. J Med Chem. 2023;66:4491\u2013502.","journal-title":"J Med Chem"},{"key":"2780_CR40","doi-asserted-by":"crossref","unstructured":"C.O. Miranda M, Rozali E, Jeya, estiri S, Al-Muftah M and Al-Ejeh F, ERK5 mediates metastatic colonization and remodeling of the tumor and tumor-immune microenvironment and immunotherapy response. Fortune J Health Sci. 2025;8.","DOI":"10.26502\/fjhs.299"},{"key":"2780_CR41","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1158\/0008-5472.CAN-16-2565","volume":"77","author":"CJ Loveridge","year":"2017","unstructured":"Loveridge CJ, Mui EJ, Patel R, Tan EH, Ahmad I, Welsh M, et al. Increased T-cell infiltration elicited by Erk5 deletion in a Pten-deficient mouse model of prostate carcinogenesis. Cancer Res. 2017;77:3158\u201368.","journal-title":"Cancer Res"},{"key":"2780_CR42","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/JLB.MR0718-269R","volume":"105","author":"I Prager","year":"2019","unstructured":"Prager I, Watzl C. Mechanisms of natural killer cell-mediated cellular cytotoxicity. J Leukoc Biol. 2019;105:1319\u201329.","journal-title":"J Leukoc Biol"},{"key":"2780_CR43","doi-asserted-by":"publisher","first-page":"896228","DOI":"10.3389\/fimmu.2022.896228","volume":"13","author":"A Ramirez-Labrada","year":"2022","unstructured":"Ramirez-Labrada A, Pesini C, Santiago L, Hidalgo S, Calvo-Perez A, Onate C, et al. All about (NK cell-mediated) death in two acts and an unexpected encore: initiation, execution and activation of adaptive immunity. Front Immunol. 2022;13:896228.","journal-title":"Front Immunol"},{"key":"2780_CR44","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.cellsig.2007.01.023","volume":"19","author":"J Borges","year":"2007","unstructured":"Borges J, Pandiella A, Esparis-Ogando A. Erk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosis. Cell Signal. 2007;19:1473\u201387.","journal-title":"Cell Signal"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-02780-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02780-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02780-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:35:25Z","timestamp":1781638525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-02780-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2780"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-02780-9","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Procedures with animals were conducted in compliance with the applicable laws, regulations, and guidelines of the Universitat Aut\u00f2noma de Barcelona (UAB) and with the approval of the Ethics Committee on Animal Experiments from UAB (ref. CEEAH 3353) and VHIR (CEEAH 4342), according to Spanish official regulations. Buffy Coats were from the Banc de Sang i Teixits of Barcelona from volunteer blood donors, with the approval of the Committee of Ethics and Clinical Investigation of the Hospital Vall d\u2019Hebron of Barcelona (PR(AG)449\/2023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"227"}}